Christine M. Bradshaw

Christine M. Bradshaw

Auto-generated profile, based on publicly available information

Christine M. Bradshaw

Department of Immunobiology, University of Arizona College of Medicine – Tucson , Tucson, AZ

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MJMladen Jergović
Mladen Jergović
JUJennifer L. Uhrlaub
Jennifer L. Uhrlaub
MWMakiko Watanabe
Makiko Watanabe
CBChristine M. Bradshaw
Christine M. Bradshaw
LWLisa M. White
Lisa M. White
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Aging is associated with a reduced magnitude of primary immune responses to vaccination. mRNA-based SARS-CoV-2 vaccines have shown efficacy in older adults but virus variant escape is still unclear. Here we analyze humoral and cellular immunity against an early-pandemic viral isolate and compare that to the P.1 (Gamma) and B.1.617.2 (Delta) variants in two cohorts (55 age) of mRNA vaccine recipients. We further measure neutralizing antibody titers for B.1.617.1 (Kappa) and B.1.595, with the latter SARS-CoV-2 isolate bearing the spike mutation E484Q. Robust humoral immunity is measured following second vaccination, and older vaccinees manifest cellular immunity comparable to the adult group against early-pandemic SARS-CoV-2 and more recent variants. More specifically, the older cohort has lower neutralizing capacity at 7-14 days following the second dose but equilibrates with the younger cohort after 2-3 months. While long-term vaccination responses remain to be determined, our results implicate vaccine-induced protection in older adults against SARS-CoV-2 variants and inform thinking about boost vaccination.

4 November 2020 in Current Opinion in Virology
Verified
Journal Article
Closed access
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
CBChristine M Bradshaw
Christine M Bradshaw
JUJennifer L Uhrlaub
Jennifer L Uhrlaub
MWMakiko Watanabe
Makiko Watanabe

15 March 2022 in Aging Cell
Verified
Journal Article
Open access
JUJennifer L. Uhrlaub
Jennifer L. Uhrlaub
MJMladen Jergović
Mladen Jergović
CBChristine M. Bradshaw
Christine M. Bradshaw
SSSandip Sonar
Sandip Sonar
SSSandip Ashok Sonar
Sandip Ashok Sonar
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Older humans and animals often exhibit reduced immune responses to infection and vaccination, and this often directly correlates to the numbers and frequency of naive T (Tn) cells. We found such a correlation between reduced numbers of blood CD8+ Tn cells and severe clinical outcomes of West Nile virus (WNV) in both humans naturally exposed to, and mice experimentally infected with, WNV. To examine possible causality, we sought to increase the number of CD8 Tn cells by treating C57BL/6 mice with IL‐7 complexes (IL‐7C, anti‐IL‐7 mAb bound to IL‐7), shown previously to efficiently increase peripheral T‐cell numbers by homeostatic proliferation. T cells underwent robust expansion following IL‐7C administration to old mice increasing the number of total T cells (>fourfold) and NS4b:H‐2Db‐restricted antigen‐specific CD8 T cells (twofold). This improved the numbers of NS4b‐specific CD8 T cells detected at the peak of the response against WNV, but not survival of WNV challenge. IL‐7C‐treated old animals also showed no improvement in WNV‐specific effector immunity (neutralizing antibody and in vivo T‐cell cytotoxicity). To test quantitative limits to which CD8 Tn cell restoration could improve protective immunity, we transferred graded doses of Ag‐specific precursors into old mice and showed that injection of 5400 (but not of 1800 or 600) adult naive WNV‐specific CD8 T cells significantly increased survival after WNV. These results set quantitative limits to the level of Tn reconstitution necessary to improve immune defense in older organisms and are discussed in light of targets of immune reconstitution.

10 January 2024 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
CBChristine M. Bradshaw
Christine M. Bradshaw
TGTeodora Georgieva
Teodora Georgieva
TTTrevor N. Tankersley
Trevor N. Tankersley
TTTama Taylor-Doyle
Tama Taylor-Doyle
LJLarry Johnson
Larry Johnson
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
A popular mouse model of COVID-19, the K18-hACE2 mouse, expresses the SARS-coronavirus entry receptor, human angiotensin-converting enzyme 2 (hACE2) driven by the keratin-18 promoter. SARS-CoV-2–infected K18-hACE2 mice exhibit neuropathology not representative of human infection. They contain eight transgene (Tg) copies, leading to excess hACE2 expression and rampant viral replication. We generated two new lines of K18-hACE2 mice encoding one and two copies of hACE2 (1-hACE2-Tg and 2-hACE2-Tg, respectively). Relative to the original strain (called 8-hACE2-Tg in this study), 2-hACE2-Tg mice exhibited lower mortality, with less viral replication in the lung and brain. Furthermore, 1-hACE2-Tg mice exhibited no mortality and had no detectable virus in the brain; yet, they exhibited clear viral replication in the lung. All three strains showed SARS-CoV-2–related weight loss commensurate with the mortality rates. 1-hACE2-Tg mice mounted detectable primary and memory T effector cell and Ab responses. We conclude that these strains provide improved models to study hACE2-mediated viral infections.

1 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
CBChristine M. Bradshaw
Christine M. Bradshaw
TGTeodora Georgieva
Teodora Georgieva
TTTrevor N. Tankersley
Trevor N. Tankersley
TTTama Taylor-Doyle
Tama Taylor-Doyle
LJLarry Johnson
Larry Johnson
JNJanko Nikolich-Žugich
Janko Nikolich-Žugich
Coronaviridae are significant human pathogens, as evidenced by several outbreaks of severe respiratory infections in the past 20 years and culminating with the COVID-19 pandemic. Mouse models of COVID-19 have included transgenic expression of the main SARS coronavirus entry receptor on human cells, human angiotensin-converting enzyme 2 (hACE2). However, the original hACE2-Tg mouse strain overexpresses many copies of the transgene, leading to neuropathology not representative of human infection. Aiming to improve physiological relevance, we generated two new lines of hACE2-Tg mice using the original transgene construct expressing hACE2 under the control of the keratin 18 promoter (K18-hACE2). We show that relative to the original strain, which expressed 8 copies of the transgene (8-hACE2-Tg), lines 1 and 2 expressed 1 and 2 copies of the transgene (1-hACE-2-Tg and 2-hACE-2-Tg, respectively). Upon intranasal (i.n.) infection with 10 3 plaque-forming units (pfu) SARS-CoV-2 WA-1/US, 8-hACE2-Tg mice succumbed to infection by d. 7. 2-hACE2-Tg mice exhibited 31% survival, with less viral replication in the lung and brain when compared to 8-hACE2-Tg mice. Furthermore, SARS-CoV-2 infection in 1-hACE2-Tg mice exhibited no mortality and had no detectable virus in the brain, although they did show clear virus replication in the lung. All three mouse strains analyzed showed SARS-CoV-2-related weight loss that tracked with the mortality rates. 1-hACE2-Tg mice mounted detectable primary and memory T effector cell and antibody responses. We conclude that these strains, particularly 1-hACE2-Tg mice, provide improved models to study hACE2-mediated viral infections.